EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations



Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations



Cancer Research 71(19): 6091-6096



Despite the perception that omega-3 fatty acids (n-3 FA) protect against breast cancer, epidemiologic studies have yielded inconsistent results. Although preclinical data have been, in general, more supportive of a protective effect of n-3 FA on breast cancer, inconsistencies still remain, which preclude definite conclusions or in-depth mechanistic investigations despite 30 years of research in this area. In this review, we discuss key variables that may account for inconsistencies of results across preclinical studies and provide recommendations for future experiments testing the chemopreventive effect of n-3 FAs in breast cancer, as part of a multiagent approach under rigorously controlled conditions.

(PDF emailed within 0-6 h: $19.90)

Accession: 036220283

Download citation: RISBibTeXText

PMID: 21933885

DOI: 10.1158/0008-5472.CAN-11-0977



Related references

Chemoprevention and oral cancer--(more) trials and (more) tribulations. European Journal of Cancer. Part B, Oral Oncology 31b(1): 1-2, 1995

Models for early chemoprevention trials in breast cancer. Hematology/Oncology Clinics of North America 12(5): 993-1017, 1999

Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience. Hematology/Oncology Clinics of North America 12(5): 1019-36, Vii, 1999

Phase III, large-scale chemoprevention trials Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer-The US National Cancer Institute experience. Hematology-Oncology Clinics of North America 12(5): 1019-1036, 1998

Trials and tribulations: do clinical trials prove that irradiation increases cardiac and secondary cancer mortality in the breast cancer patient?. International Journal of Radiation Oncology, Biology, Physics 21(2): 523-527, 1991

Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clinical Cancer Research 20(10): 2508-2515, 2015

Preclinical models for chemoprevention of colon cancer. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 163: 58-71; Discussion 264-6, 2003

Preclinical and clinical models of lung cancer chemoprevention. Hematology/Oncology Clinics of North America 12(5): 1037-1053, 1999

Preclinical mouse models for cancer chemoprevention studies. Annals of the New York Academy of Sciences 889: 14-19, 2000

Preclinical mouse models for cancer chemoprevention studies. Annals of the New York Academy of Sciences 889: 14-19, 1999

Breast cancer in older women: trials and tribulations. Clinical Oncology ) 21(2): 99-102, 2009

Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. Journal of Cellular Biochemistry 91(3): 443-458, 2004

Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762. Cancer Prevention Research, 2017

Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocrine-Related Cancer 10(3): 347-357, 2003

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Journal of the National Cancer Institute. Monographs 2010(41): 181-186, 2011